Cargando…
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
AIMS: Recent large randomized controlled trials (RCTs) have demonstrated efficacy of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) in both preventing and treating heart failure (HF). SGLT2i‐induced reversal of left ventricular remodelling has been proposed as a mechanism contributing to this ef...
Autores principales: | Dhingra, Nitish K., Mistry, Nikhil, Puar, Pankaj, Verma, Raj, Anker, Stefan, Mazer, C. David, Verma, Subodh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712921/ https://www.ncbi.nlm.nih.gov/pubmed/34623032 http://dx.doi.org/10.1002/ehf2.13645 |
Ejemplares similares
-
Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023) -
Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023) -
IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023) -
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023) -
Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)